Zim Labs appoints new President-International Business, updates senior management

Management Changes View source PDF Explain this filing

ZIMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹73.32

prior close

₹74.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+3.7%-2.1% vs market

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-0.7

15m

-0.2

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+1.6+3.7-2.1

Next day

-1.6+5.1-6.7

-2.1+4.0-6.2

-2.2+3.2-5.4

-1.5+5.9-7.4

+6.9+6.9-0.0

+0.2+5.9-5.6

15d

-6.9+2.1-9.0

-7.2-3.5-3.7

-7.1-4.2-2.9

+28.2+10.9+17.3

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zim Laboratories has appointed Mr. Vikrant Bendre as President - International Business, effective 2 Feb 2026. Bendre brings 26+ years of pharma experience, previously at JB Chemicals leading Branded Generics for international markets, and has held roles at Panacea Biotec, Jubilant Generics, and Ipca Labs. Additionally, existing VPs Jitendra Pandey (HR) and Sridhar Reddy (Quality Assurance) have been formally categorized as Senior Management Personnel.

Likely market impact

Strengthens international business leadership with an experienced external hire. Neutral to mildly positive for shareholders.